KUAN-YIN LINSZU-MIN HSIEHWANG-HUEI SHENGLo Y.-C.YU-CHUNG CHUANGARISTINE CHENGSUNG-CHING PANChen G.-J.HSIN-YUN SUNCHIEN-CHING HUNGSHAN-CHWEN CHANG2020-09-302020-09-3020180022-1899https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055442694&doi=10.1093%2finfdis%2fjiy224&partnerID=40&md5=aa4b73b96bace8ee40859e3fd984452bhttps://scholars.lib.ntu.edu.tw/handle/123456789/515770We evaluated the serologic responses to different 2-dose combinations of the inactivated hepatitis A virus (HAV) vaccines Havrix and Vaqta among human immunodeficiency virus-positive individuals during an acute hepatitis A outbreak in Taiwan. In this 16-month retrospective study, one group received 1 dose of Havrix followed by 1 dose of Vaqta, and another group received 2 doses of Vaqta. The Havrix-Vaqta and Vaqta-Vaqta groups achieved similar seroconversion rates at weeks 28-36 (82.3% and 80.9%, respectively; absolute difference, 1.3% [95% confidence interval {CI}, ?6.3%-3.7%]) and week 48 (94.7% and 94.4%, respectively; absolute difference, 0.3% [95% CI, ?2.6%-3.2%]), suggesting the interchangeability of different combinations of HAV vaccines. The significantly higher seroconversion rate after the first dose of Vaqta, compared with the dose of Havrix (53.0% vs 32.4%) may provide potential benefits in preventing HAV infection during the outbreak. ? The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.[SDGs]SDG3hepatitis A vaccine; hepatitis A vaccine; hepatitis antibody; inactivated vaccine; adult; Article; CD4 lymphocyte count; comparative study; drug effect; drug efficacy; drug response; epidemic; female; follow up; hepatitis A; human; Human immunodeficiency virus infection; major clinical study; male; priority journal; retrospective study; seroconversion; serology; Taiwan; treatment outcome; vaccination; blood; complication; epidemic; hepatitis A; Human immunodeficiency virus infection; humoral immunity; immunization; immunology; young adult; Adult; Disease Outbreaks; Hepatitis A; Hepatitis A Vaccines; Hepatitis Antibodies; HIV Infections; Humans; Immunity, Humoral; Immunization Schedule; Male; Retrospective Studies; Seroconversion; Taiwan; Treatment Outcome; Vaccines, Inactivated; Young Adultjournal article10.1093/infdis/jiy224296689512-s2.0-85055442694